BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smetana K Jr, Lacina L, Kodet O. Targeted Therapies for Melanoma. Cancers (Basel) 2020;12:E2494. [PMID: 32899184 DOI: 10.3390/cancers12092494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Betancourt LH, Gil J, Sanchez A, Doma V, Kuras M, Murillo JR, Velasquez E, Çakır U, Kim Y, Sugihara Y, Parada IP, Szeitz B, Appelqvist R, Wieslander E, Welinder C, de Almeida NP, Woldmar N, Marko-Varga M, Eriksson J, Pawłowski K, Baldetorp B, Ingvar C, Olsson H, Lundgren L, Lindberg H, Oskolas H, Lee B, Berge E, Sjögren M, Eriksson C, Kim D, Kwon HJ, Knudsen B, Rezeli M, Malm J, Hong R, Horvath P, Szász AM, Tímár J, Kárpáti S, Horvatovich P, Miliotis T, Nishimura T, Kato H, Steinfelder E, Oppermann M, Miller K, Florindi F, Zhou Q, Domont GB, Pizzatti L, Nogueira FCS, Szadai L, Németh IB, Ekedahl H, Fenyö D, Marko-Varga G. The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome. Clin Transl Med 2021;11:e451. [PMID: 34323402 DOI: 10.1002/ctm2.451] [Reference Citation Analysis]
2 Zhao K, Dai Q, Wu J, Wei Z, Duan Y, Chen B. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. Eur J Cancer 2022;165:58-70. [PMID: 35219024 DOI: 10.1016/j.ejca.2022.01.004] [Reference Citation Analysis]
3 Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, Puri N. Resistance to Molecularly Targeted Therapies in Melanoma. Cancers (Basel) 2021;13:1115. [PMID: 33807778 DOI: 10.3390/cancers13051115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]